Chapter 14
Grapefruit Juice and Its Constituents as New Esterase Inhibitors
Suresh K. Balani,
Suresh K. Balani
Department of DMPK, Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA
Search for more papers by this authorSuresh K. Balani,
Suresh K. Balani
Department of DMPK, Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA
Search for more papers by this authorBook Editor(s):Chuang Lu,
Albert P. Li,
Chuang Lu
Department of DMPK, Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA
Search for more papers by this authorAlbert P. Li
In Vitro ADMET Laboratories, Columbia, Maryland, USA
Search for more papers by this authorFirst published: 14 December 2009
Summary
This chapter contains sections titled:
-
Introduction
-
Grapefruit Juice Constituents
-
Attributes of GFJ
-
In Vitro Esterase Inhibition by GFJ
-
In Vivo Inhibition of Esterase by Gfj
-
Effects on GUT Permeability
-
Effects at the Hepatic Level
-
GFJ Flavonoids as Esterase Inhibitors
-
Utilities of GFJ Approaches
-
Clinical effects of GFJ
-
Future Scope
-
Acknowledgments
-
References
REFERENCES
- Ameer B. Grapefruit juice and kidney stones. Ann Intern Med 1998; 129: 913.
- Bailey DG, Spence JD, Edgar B, Bayliff CD, Arnold JM. Ethanol enhances the hemodynamic effects of felodipine. Clin Invest Med 1989; 12: 357–362.
- Bailey DG, Spence JD, Munoz C, Arnold JM. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991; 337: 268–269.
- Balani SK, Xu X, Pratha V, Koss MA, Amin RD, Dufresne C, Miller RR, Arison BH, Doss GA, Chiba M, Freeman A, Holland SD, Schwartz JI, Lasseter KC, Gertz BJ, Isenberg JI, Rogers JD, Lin JH, Baillie TA. Metabolic profiles of Montelukast Sodium (Singulair), a potent cysteinyl leukotriene1 receptor antagonist, in human plasma and bile. Drug Metab Dispos 1997; 25: 1282–1287.
- Banfield C, Gupta S, Marino M, Lim J, Affrime M. Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine. Clin Pharmacokinet 2002; 41: 311–318.
- Beaumont K, Webster R, Gardner I, Dack K. Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist. Curr Drug Metab 2003; 4: 461–485.
- Benavente-García O, Castillo J, Alcaraz M, Vicente V, Del Río JA, Ortuño A. Beneficial action of Citrus flavonoids on multiple cancer-related biological pathways. Curr Cancer Drug Targets 2007; 7: 795–809.
- Benavente-García O, Castillo J. Beneficial action of citrus flavonoids on multiple cancer-related biological pathways. Update on uses and properties of citrus flavonoids: new findings in anticancer, cardiovascular, and anti-inflammatory activity. J Agric Food Chem 2008; 56: 6185–6205.
- Brunner LJ, Munar MY, Vallian J, Wolfson M, Stennett DJ, Meyer MM, Bennett WM. Interaction between cyclosporine and grapefruit juice requires long-term ingestion in stable renal transplant recipients. Pharmacotherapy 1998; 18: 23–29.
- Calogeropoulou T, Detsi A, Lekkas E, Koufaki M. Strategies in the design of prodrugs of anti-HIV agents. Curr Top Med Chem 2003; 3: 1467–1495.
- Cerda JJ, Robbins FL, Burgin CW, Baumgartner TG, Rice RW. The effects of grapefruit pectin on patients at risk for coronary heart disease without altering diet or lifestyle. Clin Cardiol 1988; 11: 589–594.
- Cerda JJ, Normann SJ, Sullivan MP, Burgin CW, Robbins FL, Vathada S, Leelachaikul P. Inhibition of atherosclerosis by dietary pectin in microswine with sustained hypercholesterolemia. Circulation 1994; 89: 1247–1253.
- Curhan GC, Willett WC, Rimm EB, Spiegelman D, Stampfer MJ. Prospective study of beverage use and the risk of kidney stones. Am J Epidemiol 1996; 143: 240–247.
- Curhan GC, Willett WC, Speizer FE, Stampfer MJ. Beverage use and risk for kidney stones in women. Ann Intern Med 1998; 128: 534–540.
- De Castro WV, Mertens-Talcott S, Rubner A, Butterweck V, Derendorf HJ. Variation of flavonoids and furanocoumarins in grapefruit juices: a potential source of variability in grapefruit juice–drug interaction studies. Agric Food Chem 2006; 11: 249–255.
- De Castro WV, Mertens-Talcott S, Derendorf H, Butterweck V. Grapefruit juice–drug interactions: Grapefruit juice and its components inhibit P-glycoprotein (ABCB1) mediated transport of talinolol in Caco-2 cells. J Pharm Sci 2007; 96: 2808–2817.
- De Castro WV, Mertens-Talcott S, Derendorf H, Butterweck V. Effect of grapefruit juice, naringin, naringenin, and bergamottin on the intestinal carrier-mediated transport of talinolol in rats. J Agric Food Chem 2008; 56: 4840–4845.
- Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, Kim RB. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 2002; 71: 11–20.
- Ducharme MP, Warbasse LH, Edwards DJ. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther 1995; 57: 485–491.
- Fuhr U, Kummert AL. The fate of naringin in humans: a key to grapefruit juice–drug interactions? Clin Pharmacol Ther 1995; 58: 365–373.
- Gattuso G, Barreca D, Gargiulli C, Leuzzi U, Caristi C. Flavonoid composition of citrus juices. Molecule 2007; 12: 1641–1673.
- Glaeser H, Bailey DG, Dresser GK, Gregor JC, Schwarz UI, McGrath JS, Jolicoeur E, Lee W, Leake BF, Tirona RG, Kim RB. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther 2007; 81: 362–370.
- Greenblatt DJ, von Moltke LL, Harmatz JS, Chen G, Weemhoff JL, Jen C, Kelley CJ, LeDuc BW, Zinny MA. Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice. Clin Pharmacol Ther 2003; 74: 121–129.
- Guo LQ, Fukuda K, Ohta T, Yamazoe Y. Role of furanocoumarin derivatives on grapefruit juice-mediated inhibition of human CYP3A activity. Drug Metab Dispos 2000; 28: 766–771.
- Guthrie N, Carol KK. Inhibition of mammary cancer by citrus flavonoids. Adv Exp Med Biol 1998; 439: 227–236.
- Hall SD, Thummel KE, Watkins PB, Lown KS, Benet LZ, Paine MF, Mayo RR, Turgeon DK, Bailey DG, Fontana RJ, Wrighton SA, Fontana RJ, Wrighton SA. Molecular and physical mechanisms of first-pass extraction. Drug Metab Dispos 1999; 27: 161–166.
- Hatfield JM, Wierdl M, Wadkins RM, Potter PM. Modifications of human carboxylesterase for improved prodrug activation. Expert Opin Drug Metab Toxicol 2008; 4: 1153–1165.
- He K, Iyer KR, Hayes RN, Sinz MW, Woolf TF, Hollenberg PF. Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem Res Toxicol 1998; 11: 252–259.
- Ho PC, Saville DJ, Wanwimolruk S. Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds. J Pharm Pharm Sci 2001; 4: 217–227.
- Hosokawa M. Structure and catalytic properties of carboxylesterase isozymes involved in metabolic activation of prodrugs. Molecules 2008; 13: 412–431.
- Huang SH, Hall SD, Watkins P, Love LA, Serabjit-Singh C, Betz JM, Hoffman FA, Honig P, Coates PM, Bull J, Chen ST, Kearns GL, Murray MD. Drug interactions with herbal prodrugs and grapefruit juice: a conference report. Clin Pharmacol Ther 2004; 75: 1–12.
- Kane GC, Lipsky JJ. Drug—grapefruit juice interaction. Mayo Clin Proc 2000; 75: 933–942.
- Kuhnau J. The flavonoids: a class of semi-essential food components; their role in human nutrition. World Rev Nutr Diet 1976; 24: 117–191.
- Li P, Callery PS, Gan L-S, Balani SK. Esterase inhibition by grapefruit juice leading to a new drug interaction. Drug Metab Dispos 2007a; 35: 1023–1031.
- Li P, Callery PS, Gan L-S, Balani SK. Esterase inhibition by grapefruit juice flavonoids leading to a new drug interaction. Drug Metab Dispos 2007b; 35: 1203–1208.
- Liederer BM, Borchardt RT. Enzymes involved in the bioconversion of ester-based prodrugs. J Pharm Sci 2006; 95: 1177–1195.
- Lin H-L, Kent UM, Hollenberg PF. The grapefruit juice effect is not limited to cytochrome P450 (P450) 3A4: evidence for bergamottin-dependent inactivation, heme destruction, and covalent binding to protein in P450s 2B6 and 3A5. J Pharm Exp Ther 2005; 313: 154–164.
- Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, Brown MB, Guo W, Watkins PB. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 1997; 99: 2545–2553.
- Manthey JA, Buslig BS. Distribution of furanocoumarins in grapefruit juice fractions. J Agric Food Chem 2005; 53: 5158–5163.
- Mertens-Talcott SU, De Castro WV, Manthey JA, Derendorf H, Butterweck V. Polymethoxylated flavones and other phenolic derivates from citrus in their inhibitory effects on P-glycoprotein-mediated transport of talinolol in Caco-2 cells. J Agric Food Chem 2007; 55: 2563–2568.
- Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34: 1274–1281.
- Mohri K, Uesawa Y, Sagawa K-I. Effects of long-term grapefruit juice ingestion on nifedipine pharmacokinetics: induction of rat hepatic P-450 by grapefruit juice. Drug Metab Dispos 2000; 28: 482–486.
- Morishita Y, Fujii M, Kasakura Y, Takayama T. Effect of carboxylesterase inhibition on anti-tumour effects of irinotecan. J Int Med Res 2005; 33: 84–89.
- Paine MF, Widmer WW, Hart HL, Pusek SN, Beavers KL, Criss AB, Brown SS, Thomas BF, Watkins PB. A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction. Am J Clin Nutr 2006; 83: 1097–2105.
- Quinney SK, Sanghani SP, Davis WI, Hurley TD, Sun Z, Murry DJ, Bosron WF. Hydrolysis of Capecitabine to 5′-deoxy-5-fluorocytidine by human carboxylesterases and inhibition by Loperamide. J Pharm Exp Ther 2005; 313: 1011–1016.
- Ranganna S, Govindarajan VS, Ramana KV. Citrus fruits—varieties, chemistry, technology, and quality evaluation. Part II. Chemistry, technology, and quality evaluation. A Chemistry. Crit Rev Food Sci Nutr 1983; 18: 313–386.
- Ross SA, Ziska DS, Zhao K, El Sohly MA. Variance of common flavonoids by brand of grapefruit juice. Fitoterapia 2000; 71: 154–161.
- Saito M, Hirata-Koizumi M, Matsumoto M, Urano T, Hasegawa R. Undesirable effects of citrus juice on the pharmacokinetics of drugs: focus on recent studies. Drug Saf 2005; 28: 677–694.
- Satoh T, Hosokawa M. The mammalian carboxylesterases: from molecules to functions. Annu Rev Pharmacol Toxicol 1998; 38: 257–288.
- Satoh T, Taylor P, Bosron WF, Sanghani SP, Hosokawa M, La Du BN. Current progress on esterases: from molecular structure to function. Drug Metab Dispos 2002; 30: 488–493.
- Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, He K, Lown KS, Woster PM, Rahman A, Thummel KE, Fisher JM, Hollenberg PF, Watkins PB. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos 1997; 25: 1228–1233.
- Sharma V, Joseph C, Ghosh S, Agarwa Al, Mishra MK, Sen E. Kaempferol induces apoptosis in glioblastoma cells through oxidative stress. Mol Cancer Ther 2007; 6: 2544–2553.
- Shaw PE, Moshonas MG, Heran CJ, Goodner KL. Volatile constituents in fresh and processed juices from grapefruit and new grapefruit hybrids. J Agric Food Chem 2000; 48: 2425–2429.
- Siegelin MD, Reuss DE, Habel A, Herold-Mende C, von Deimling A. The flavonoid kaempferol sensitizes human glioma cells to TRAIL-mediated apoptosis by proteasomal degradation of surviving. Mol Cancer Ther 2008; 7: 3566–3574.
- So FV, Guthrie N, Chambers AF, Moussa M, Carol KK. Inhibition of human cancer cell proliferation and delay of mammary cell tumorigenesis by flavonoids and citrus juices. Nutr Cancer 1996; 26: 167–181.
- Spahn-Langguth H, Langguth P. Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol. Eur J Pharm Sci 2001; 12: 361–367.
- Stoeckel K, Hofheinz W, Laneury JP, Duchene P, Shedlofsky S, Blouin RA. Stability of cephalosporin prodrug esters in human intestinal juice: Implications for oral bioavailability. Antimicrob Agents Chem 1998; 42: 2602–2606.
- Takanaga H, Ohnishi A, Matsuo H, Sawada Y. Inhibition of vinblastine efflux mediated by p-glycoprotein by grapefruit juice components in Caco-2 cells. Biol Pharm Bull 1998; 21: 1062–1066.
- Takanaga H, Ohnishi A, Yamada S, Matsuo H, Morimoto S, Shoyama Y, Ohtani H, Sawada Y. Polymethoxylated flavones in orange juice are inhibitors of p-glycoprotein but not cytochrome P450 3A4. J Pharmacol Exp Ther 2000a; 293: 230–236.
- Takanaga H, Ohnishi A, Matsuo H, Murakami H, Sata H, Kuroda K, Urae A, Higuchi S, Sawada Y. Pharmacokinetic analysis of felodipine—grapefruit juice interaction based on an irreversible enzyme inhibition model. Br J Clin Pharmacol 2000b; 49: 49–58.
- Takanaga H, Ohnishi A, Murakami H, Matsuo H, Higuchi S, Urae A, Irie S, Furuie H, Matsukuma K, Kimura M, Kawano K, Orii Y, Tanaka T, Sawada Y. Relationship between time after intake of grapefruit juice and the effect on pharmacokinetics and pharmacodynamics of nisoldipine in healthy subjects. Clin Pharmacol Ther 2000c; 67: 201–214.
- Tassaneeyakul W, Guo LQ, Fukuda K, Ohta T, Yamazoe Y. Inhibition selectivity of grapefruit juice components on human cytochromes P450. Arch Biochem Biophys 2000; 378: 356–363.
- Uno T, Yasui-Furukori N. Effect of grapefruit juice in relation to human pharmacokinetic study. Curr Clin Pharmacol 2006; 1: 157–161.
- Van Gelder J, Annaert P, Naesens L, De Clercq E, Van den Mooter G, Kinget R, Augustijns P. Inhibition of intestinal metabolism of the antiviral ester prodrug bis(POC)-PMPA by nature—identical fruit extracts as a strategy to enhance its oral absorption: an in vitro study. Pharm Res 1999; 16: 1035–1040.
- Van Gelder J, Deferme S, Annaert P, Naesens L, De Clercq E, Van den Mooter G, Kinget R, Augustijns P. Increased absorption of the antiviral ester prodrug tenofovir disoproxil in rat ileum by inhibiting its intestinal metabolism. Drug Metab Dispos 2000; 28: 1394–1396.
- Van Gelder J, Deferme S, Annaert P, Naesens L, De Clercq E, Van den Mooter G, Kinget R, Augustijns P. Intestinal absorption enhancement of the ester prodrug tenofovir disoproxil fumerate through modulation of the biochemical barrier by defined ester mixtures. Drug Metab Dispos 2002; 30: 924–930.
- Veronese ML, Gillen LP, Burke JP, Dorval EP, Hauck WW, Pequignot E, Waldman SA, Greenberg HE. Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice. J Clin Pharmacol 2003; 43: 831–839.
- Verweij J. Rational design of new tumoractivated cytotoxic agents. Oncology 1999; 57: 9–15.
- Wadkins RM, Hyatt JL, Yoon KJ, Morton CL, Lee RE, Damodaran K, Beroza P, Danks MK, Potter PM. Discovery of novel selective inhibitors of human intestinal carboxyl esterase for the amelioration of irinotecan-induced diarrhea: synthesis, quantitative structure—activity relationship analysis, and biological activity. Mol Pharmacol 2004; 65: 1336–1343.
- Wadkins RM, Hyatt JL, Wei X, Yoon KJ, Wierdl M, Edwards CC, Morton CL, Obenauer JC, Damodaran K, Beroza P, Danks MK, Potter PM. Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem 2005; 48: 2906–2915.
- Walker CH, Mackness MI. Esterase: problems of identification and classification. Biochem Pharmacol 1983; 32: 3265–3269.
- Xie M, Yang D, Liu L, Xue B, Yan B. Human and rodent carboxylesterases: immunorelatedness, overlapping substrate specificity, differential sensitivity to serine enzyme inhibitors, and tumor-related expression. Drug Metab Dispos 2002; 30: 541–547.
- Yang J, Liao M, Shou M, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A. Cytochrome P450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Curr Drug Metab 2008; 9: 384–393.
- Zhou S, Lim LY, Chowbay B. Herbal modulation of P-glycoprotein. Drug Metab Rev 2004; 36: 57–104.
